MedTrace Logo

Personalized Anti-Inflammatory Fibres in Ulcerative Colitis

NCT06515210 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients with ulcerative colitis. The main question it aims to answer is: Can the fibre supplements reduce gut inflammation (fecal calprotectin)?

Researchers will compare AG and MCC to a placebo (a look-alike substance that contains no fibre) to see if the fibre supplements improve inflammation in ulcerative colitis.

Participants will add their assigned fibre supplement or placebo to their usual diet daily for 6 weeks. They will visit the clinic at baseline, week 3, and week 6 to provide samples (stool, blood) and complete various questionnaires.

Conditions

Interventions

DIETARY_SUPPLEMENT

Acacia Gum

Participants (n=23) incorporate the fibre supplement into their usual diet daily.

DIETARY_SUPPLEMENT

Microcrystalline Cellulose

Participants (n=23) incorporate the fibre supplement into their usual diet daily.

DIETARY_SUPPLEMENT

Placebo

Participants (n=23) incorporate the placebo into their usual diet daily.

Sponsors & Collaborators

  • Weston Family Foundation

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Eytan Wine, MD, PhD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06515210 on ClinicalTrials.gov